<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159976</url>
  </required_header>
  <id_info>
    <org_study_id>B-1403/243-003</org_study_id>
    <nct_id>NCT02159976</nct_id>
  </id_info>
  <brief_title>Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea</brief_title>
  <official_title>A Prospective, Multi-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare 10-day Sequential Therapy and 14-day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SK Chemicals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To compare 10-day sequential therapy and 14-day modified bismuth quadruple therapy and
           to establish more effective first-line regimen for the eradication of Helicobacter
           pylori in Korea.

        2. To evaluate the effect of H. pylori eradication therapy on the symptom improvement of
           functional dyspepsia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emerging evidence shows that the eradication rate of proton pump inhibitor (PPI)-based triple
      therapy for the first-line treatment of Helicobacter pylori has decreased. The reason for the
      decrease in the efficacy of PPI-based triple therapy is mainly due to the increase in the
      resistance against clarithromycin. Sequential therapy seems to be more effective than the
      PPI-based triple therapy, however, the eradication rate of sequential therapy in Korea, which
      is mostly under 80%, is still not satisfactory. Modified bismuth quadruple therapy which
      replace metronidazole with amoxicillin (contained PPI, bismuth, tetracycline and amoxicillin)
      can be a promising regimen because the antibiotic resistance rate of tetracycline and
      amoxicillin are relatively low in Korea and amoxicillin is more easy to take in comparing
      with metronidazole. Therefore, the aim of this study is to compare 10-day sequential therapy
      and 14-day modified bismuth quadruple therapy and to establish more effective first-line
      regimen for the eradication of Helicobacter pylori in Korea.

      In addition, previous studies reported that H. pylori infection also associated with
      functional dyspepsia (FD) and recommended H. pylori eradication in patients with FD. However,
      until now, there was no randomized prospective study in Korea, therefore the another aim of
      this study is to evaluate the effect of H. pylori eradication therapy on the symptom
      improvement of FD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Counts of Participants With Successful H. Pylori Eradication</measure>
    <time_frame>4 weeks after termination of eradication therapy, up to 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Counts of Participants Whose Drug Compliance is More Than 85%</measure>
    <time_frame>4 weeks after termination of eradication therapy, up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Counts of Participants With Adverse Event</measure>
    <time_frame>4 weeks after termination of eradication therapy, up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Dyspepsia Symptom Responses Rate</measure>
    <time_frame>1 year after termination of eradication therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Sequential therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified bismuth quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>Pantoprazole 40mg bid</description>
    <arm_group_label>Modified bismuth quadruple therapy</arm_group_label>
    <arm_group_label>Sequential therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin 1000mg bid</description>
    <arm_group_label>Modified bismuth quadruple therapy</arm_group_label>
    <arm_group_label>Sequential therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Clarithromycin 500mg bid</description>
    <arm_group_label>Sequential therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole 500mg tid</description>
    <arm_group_label>Sequential therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline</intervention_name>
    <description>Tetracycline 1000mg bid</description>
    <arm_group_label>Modified bismuth quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth</intervention_name>
    <description>Bismuth 600mg bid</description>
    <arm_group_label>Modified bismuth quadruple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female Korean Adult (Aged ≥ 18 years)

          -  Patients who diagnosis of H. pylori infection by any of following three methods

               -  positive rapid urease test (CLOtest)

               -  histologic evidence of H. pylori by modified Giemsa staining

               -  positive 13C-urea breath test

        Exclusion Criteria:

          -  Age under 18 years

          -  Previous eradication treatment for H. pylori

          -  Patients who took any drug which could influence the study results such as proton pump
             inhibitor, H2 blocker, mucosal protective agent and antibiotics

          -  History of gastrectomy

          -  Advanced gastric cancer or other malignancy

          -  Abnormal liver function or liver cirrhosis

          -  Abnormal renal function or chronic kidney disease

          -  Other severe concurrent diseases

          -  Previous allergic reactions to the study drugs

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 3, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <results_first_submitted>May 5, 2016</results_first_submitted>
  <results_first_submitted_qc>February 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2019</results_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Nayoung Kim</investigator_full_name>
    <investigator_title>Professor, M.D, Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequential Therapy</title>
          <description>pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
Pantoprazole
Amoxicillin
Clarithromycin
Metronidazole</description>
        </group>
        <group group_id="P2">
          <title>Modified Bismuth Quadruple Therapy</title>
          <description>pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
Pantoprazole
Amoxicillin
Tetracycline
Bismuth</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequential Therapy</title>
          <description>pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
Pantoprazole
Amoxicillin
Clarithromycin
Metronidazole</description>
        </group>
        <group group_id="B2">
          <title>Modified Bismuth Quadruple Therapy</title>
          <description>pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
Pantoprazole
Amoxicillin
Tetracycline
Bismuth</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="195"/>
            <count group_id="B2" value="195"/>
            <count group_id="B3" value="390"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="304"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="12.6"/>
                    <measurement group_id="B2" value="53.6" spread="13.2"/>
                    <measurement group_id="B3" value="53.4" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Counts of Participants With Successful H. Pylori Eradication</title>
        <time_frame>4 weeks after termination of eradication therapy, up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequential Therapy</title>
            <description>pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
Pantoprazole
Amoxicillin
Clarithromycin
Metronidazole</description>
          </group>
          <group group_id="O2">
            <title>Modified Bismuth Quadruple Therapy</title>
            <description>pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
Pantoprazole
Amoxicillin
Tetracycline
Bismuth</description>
          </group>
        </group_list>
        <measure>
          <title>Counts of Participants With Successful H. Pylori Eradication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Counts of Participants Whose Drug Compliance is More Than 85%</title>
        <time_frame>4 weeks after termination of eradication therapy, up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequential Therapy</title>
            <description>pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
Pantoprazole
Amoxicillin
Clarithromycin
Metronidazole</description>
          </group>
          <group group_id="O2">
            <title>Modified Bismuth Quadruple Therapy</title>
            <description>pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
Pantoprazole
Amoxicillin
Tetracycline
Bismuth</description>
          </group>
        </group_list>
        <measure>
          <title>Counts of Participants Whose Drug Compliance is More Than 85%</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Counts of Participants With Adverse Event</title>
        <time_frame>4 weeks after termination of eradication therapy, up to 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sequential Therapy</title>
            <description>pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
Pantoprazole
Amoxicillin
Clarithromycin
Metronidazole</description>
          </group>
          <group group_id="O2">
            <title>Modified Bismuth Quadruple Therapy</title>
            <description>pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
Pantoprazole
Amoxicillin
Tetracycline
Bismuth</description>
          </group>
        </group_list>
        <measure>
          <title>Counts of Participants With Adverse Event</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Dyspepsia Symptom Responses Rate</title>
        <time_frame>1 year after termination of eradication therapy</time_frame>
        <population>SQT and PBAT were used for the initial treatment. Thereafter, treatment success and treatment failure group were divided. In the treatment failure group, secondary treatment was performed. Secondary endpoints were functional and dyspepsia symptom responses rate after successful treatment, not success in both treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>In Eradication Success Group</title>
            <description>functional dyspepsia symptom responses rate in eradication success group</description>
          </group>
          <group group_id="O2">
            <title>In Eradication Failure Group</title>
            <description>functional dyspepsia symptom responses rate in eradication failure group</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Dyspepsia Symptom Responses Rate</title>
          <population>SQT and PBAT were used for the initial treatment. Thereafter, treatment success and treatment failure group were divided. In the treatment failure group, secondary treatment was performed. Secondary endpoints were functional and dyspepsia symptom responses rate after successful treatment, not success in both treatment groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>complete (≥75%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory (50-74%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial (25-49%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refractory (&lt;25%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sequential Therapy</title>
          <description>pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
Pantoprazole
Amoxicillin
Clarithromycin
Metronidazole</description>
        </group>
        <group group_id="E2">
          <title>Modified Bismuth Quadruple Therapy</title>
          <description>pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
Pantoprazole
Amoxicillin
Tetracycline
Bismuth</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Epigastric soreness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Taste distortions</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Stool color change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="195"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash and itching</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="195"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nayoung Kim, M.D., Ph.D.</name_or_title>
      <organization>Department of Internal Medicine, Seoul National University Bundang Hospital</organization>
      <phone>+ 82-31-787-7008</phone>
      <email>nayoungkim49@empas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

